FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease. U.S. Food and Drug Administration approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise.\u00a0NASH is a result of the progression of nonalcoholic fatty liver disease where liver inflammation, over time, can lead to liver scarring and liver dysfunction. NASH is often associated with other health problems such as high blood pressure and type 2 diabetes.<\/p>\n
If REZDIFFRA (resmetirom) tablets\u00a0<\/strong>are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n Note:<\/strong><\/em> REZDIFFRA (resmetirom) is used to treat a certain liver disease (nonalcoholic steatohepatitis-NASH)<\/b>. In people with NASH, fat builds up in the liver leading to inflammation and more serious liver problems over time. Resmetirom works by decreasing the buildup of fat in the liver and may help prevent further liver damage.<\/p>\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"REZDIFFRA (resmetirom) tablets, for oral use Initial U.S. Approval: 2024<\/h2>\n